What is BioStable Science & Engineering?
BioStable Science & Engineering is a cardiovascular device company dedicated to the development and commercialization of proprietary valve repair technologies. These innovative solutions aim to offer a viable alternative to valve replacement for patients suffering from aortic valve disease. The company's HAART Aortic Repair Technologies are engineered to streamline and standardize the aortic valve repair process, thereby empowering surgeons to extend the recognized clinical advantages of valve repair to patients undergoing surgical correction for aortic insufficiency or aortic aneurysm.
How much funding has BioStable Science & Engineering raised?
BioStable Science & Engineering has raised a total of $14M across 3 funding rounds:
Series A
$5.5M
Series B
$4.3M
Series C
$4.2M
Series A (2008): $5.5M with participation from Sante Ventures
Series B (2015): $4.3M led by Sante Ventures
Series C (2020): $4.2M supported by Rex Health Ventures and Orlando Health Ventures
Key Investors in BioStable Science & Engineering
Sante Ventures
Sante Ventures is a venture capital firm that invests in innovative healthcare enterprises, with a specific focus on Biotech, Medtech, and Healthtech sectors. They manage substantial capital to enhance patient health outcomes through strategic investments in emerging technologies.
Rex Health Ventures
Rex Health Ventures is associated with UNC REX Healthcare, a private, not-for-profit health care system founded in 1894, indicating a strategic interest in healthcare innovation and patient care technologies.
Orlando Health Ventures
Orlando Health Ventures is an investment arm likely focused on advancing healthcare solutions and technologies, though specific details on their investment focus are not provided.
What's next for BioStable Science & Engineering?
With the recent major strategic investment, BioStable Science & Engineering is poised to accelerate its commercialization efforts and further refine its HAART Aortic Repair Technologies. This enterprise-level funding suggests a transition towards scaling operations, expanding market reach, and potentially pursuing further clinical validation or regulatory approvals. The company's focus on providing an alternative to valve replacement aligns with a growing trend in healthcare towards less invasive and more patient-centric treatment options, positioning BioStable for significant impact in the cardiovascular medical device market.
See full BioStable Science & Engineering company page
